TOM FROHLICH

Tom Frohlich has more than 25 years of leadership experience across multinational pharmaceutical and emerging biotech companies. He co-founded Chinook Therapeutics in 2019 and served as chief operating officer until Chinook’s acquisition by Novartis. He is currently on the board of Nested Therapeutics.

Since 2018, Mr. Frohlich has also served as an operating principal and subsequently as an entrepreneur-in-residence at Versant Ventures, a healthcare investment firm. Prior to Chinook, he was vice president of business development at Arbutus Biopharma, where he played a key role in multiple transactions including the merger of Tekmira/Oncore and the spin-out of Genevant. Previously, Mr. Frohlich worked internationally at Johnson and Johnson and Merck in various roles leading commercial strategy across all stages of product development including the global launches of telaprevir and STELARA® (ustekinumab).

Mr. Frohlich has a B.Sc. in biochemistry from the University of Victoria and an MBA from the University of Oxford.